{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:48:54Z","timestamp":1791838134744,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2020028"],"award-info":[{"award-number":["2020028"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.08.073","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:13:09Z","timestamp":1788995589000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-to-Kidney Absorbed Dose Ratios for Alpha-Emitter PRRTs Estimated With [177Lu]Lu-DOTATATE SPECT Images and Biokinetic Models: Patient Variations Impact Contribution From Redistributing Daughters"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-1980","authenticated-orcid":false,"given":"Monika","family":"Kvassheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Karlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Blakkisrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.08.073_bib0001","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/ph17030334","article-title":"Towards effective targeted alpha therapy for neuroendocrine tumours: A review","volume":"17","author":"Gape","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0002","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.3390\/molecules27175429","article-title":"Radionuclides for targeted therapy: Physical properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0003","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-Octreotate treatment","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0146645315577539","article-title":"ICRP publication 130: Occupational intakes of radionuclides: Part 1","volume":"44","author":"Paquet","year":"2015","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0146645317734963","article-title":"ICRP publication 137: Occupational intakes of radionuclides: Part 3","volume":"46","author":"Paquet","year":"2017","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0146645319834139","article-title":"ICRP publication 141: Occupational intakes of radionuclides: Part 4","volume":"48","author":"Paquet","year":"2019","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0007","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/01466453211028755","article-title":"Occupational intakes of radionuclides: Part 5","volume":"51","author":"Paquet","year":"2022","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0008","first-page":"7","article-title":"ICRP publication 107. Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0009","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2026.08.073_bib0010","first-page":"129","article-title":"225Ac-DOTATATE (RYZ101) dosimetry results from part 1 of the ACTION-1 trial","volume":"64","author":"Sgouros","year":"2023","journal-title":"J Nucl Med."},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0011","article-title":"EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters","volume":"2","author":"Gabi\u00f1a","year":"2026","journal-title":"EANM Innov."},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0012","first-page":"1","article-title":"Age-dependent doses to members of the public from intake of radionuclides: Part 2. Ingestion dose coefficients. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection","volume":"23","year":"1993","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0013","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nucmedbio.2012.02.003","article-title":"Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice","volume":"39","author":"Svensson","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41181-016-0008-2","article-title":"Alpha-PET with terbium-149: Evidence and perspectives for radiotheragnostics","volume":"1","author":"M\u00fcller","year":"2017","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0015","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.peptides.2004.08.018","article-title":"Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: Potential peptide radiotherapeutics for somatostatin receptor-positive cancers","volume":"25","author":"Vaidyanathan","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0016","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.bmc.2018.01.023","article-title":"Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment","volume":"26","author":"Zhao","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0017","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/acs.molpharmaceut.3c00427","article-title":"Effective treatment of SSTR2-positive small cell lung cancer using 211At-containing targeted \u03b1-particle therapy agent which promotes endogenous antitumor immune response","volume":"20","author":"Qin","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0018","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.2967\/jnumed.124.267999","article-title":"Preclinical evaluation of 226Ac as a theranostic agent: Imaging, dosimetry, and therapy","volume":"65","author":"Koniar","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0019","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"\u00b2\u00b9\u00b3Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0020","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: First-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0021","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: First clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0022","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted \u03b1-therapy and capecitabine: A real-world scenario management-based long-term outcome study","volume":"64","author":"Ballal","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0023","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4274\/mirt.galenos.2023.38258","article-title":"Initial findings on the use of [225Ac]Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors","volume":"32","author":"Demirci","year":"2023","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0025","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: A pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.08.073_bib0026","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.121.262687","article-title":"Harnessing \u03b1-emitting radionuclides for therapy: Radiolabeling method review","volume":"63","author":"Yang","year":"2022","journal-title":"J Nucl Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626042914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626042914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:32:18Z","timestamp":1791837138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626042914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0360301626042914"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.08.073","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-to-Kidney Absorbed Dose Ratios for Alpha-Emitter PRRTs Estimated With [177Lu]Lu-DOTATATE SPECT Images and Biokinetic Models: Patient Variations Impact Contribution From Redistributing Daughters","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.08.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}